Medicare Part B International Reference Pricing Model

Executive Summary

This model proposes a comprehensive Medicare Part B drug reimbursement system that incorporates international reference pricing (IRP) to reduce drug costs while maintaining beneficiary access and preserving innovation incentives. The model builds upon previous CMMI initiatives and international best practices to create a sustainable pricing framework.

Model Overview

Name

Medicare Part B Global Price Alignment Model (GPAM)

Duration

5-year demonstration period (2026-2031) with potential for expansion

Scope

• Initially covers single-source drugs and biologicals in Medicare Part B
• Phased expansion to include high-cost specialty drugs
• Voluntary participation for first 2 years, then mandatory in selected regions

Key Components

1. International Reference Pricing Framework

Reference Country Basket

• Tier 1 Countries (Primary comparators - 60% weight):
  • Canada
  • United Kingdom
  • Germany
  • Japan
  • France
  • Australia
• Tier 2 Countries (Secondary comparators - 40% weight):
  • Netherlands
  • Switzerland
  • Sweden
  • Belgium
  • Austria
  • Denmark

Pricing Methodology

• Calculate weighted average of ex-manufacturer prices from reference countries
• Apply GDP per capita adjustment factor
• Set ceiling at 130% of international reference price average
• Floor at 65% of current ASP to prevent market disruption

2. Phased Implementation

Year 1-2 (2026-2027): Foundation Phase

• Voluntary participation
• Focus on 50 highest-spend Part B drugs
• Payment = 80% ASP + 20% IRP
• Enhanced add-on payments for participants

Year 3-4 (2028-2029): Expansion Phase

• Mandatory in selected regions
• Expand to 150 drugs
• Payment = 50% ASP + 50% IRP
• Introduction of vendor model option

Year 5 (2030-2031): Full Implementation

• National rollout consideration
• Payment = 30% ASP + 70% IRP
• Complete vendor integration

3. Alternative Distribution Model

Private Vendor System

• CMS contracts with 3-5 national vendors
• Vendors negotiate directly with manufacturers
• Take title to drugs and distribute to providers
• Compete on service quality and efficiency

Provider Options

• Continue buy-and-bill with IRP pricing
• Opt into vendor model for reduced administrative burden
• Hybrid approach for different drug categories

4. Provider Payment Restructuring

Current System Problems

• 4.3% post-sequester add-on creates perverse incentives
• Providers face financial risk from drug acquisition

New Payment Structure

• Fixed service fee per administration ($150-$500 based on complexity)
• Quality bonuses for appropriate utilization
• Risk mitigation fund for small/rural providers
• No financial incentive to choose higher-cost drugs

5. Beneficiary Protections

Cost-Sharing Improvements

• 20% coinsurance based on IRP, not ASP
• Annual out-of-pocket cap of $3,000 for Part B drugs
• Catastrophic coverage after cap reached
• No cost-sharing for preventive medications

Access Safeguards

• Exceptions process for clinical necessity
• Protected class designations for critical therapies
• Rural access fund to ensure availability
• Patient assistance program coordination

6. Innovation and Access Provisions

New Drug Entry

• 2-year exemption from IRP for truly innovative drugs
• Accelerated approval pathway participation
• Enhanced reimbursement for breakthrough therapies
• Outcomes-based contracts option

Biosimilar Incentives

• Shared savings program for biosimilar adoption
• Provider education and support
• Streamlined coding and billing
• Enhanced add-on for first 2 years

7. Data and Transparency Requirements

Manufacturer Obligations

• Submit international pricing data quarterly
• Report on R&D investments
• Disclose patient assistance programs
• Provide access metrics

Public Reporting

• Dashboard showing price comparisons
• Savings achieved by drug and region
• Access and utilization metrics
• Innovation pipeline impacts

8. Quality and Monitoring Framework

Key Performance Indicators

• Drug spending reduction (target: 30% by year 5)
• Beneficiary access rates (maintain >95%)
• Provider participation and satisfaction
• Time to market for new drugs

Evaluation Metrics

• Total Part B drug spending
• Beneficiary out-of-pocket costs
• Health outcomes by therapeutic area
• Provider practice patterns
• Innovation pipeline analysis

9. Legal and Regulatory Considerations

Statutory Authority

• Innovation Center testing authority under Section 1115A
• Alignment with IRA provisions
• Coordination with existing Part B rules

Safeguards Against Legal Challenges

• Voluntary phase allows market adjustment
• Maintains fee-for-service structure
• Preserves provider choice
• Clear hardship exemptions

10. Special Provisions

Cancer Care Protection

• Oncology drugs phased in last
• Enhanced clinical pathways support
• Outcomes-based payment options
• Precision medicine considerations

Rare Disease Accommodations

• Orphan drug exemptions (first indication only)
• Ultra-rare disease carve-outs
• Patient registry requirements
• Specialized distribution networks

Implementation Timeline

2025: Preparation Year

• Q1-Q2: Stakeholder engagement and model refinement
• Q3: Vendor procurement process
• Q4: Provider enrollment begins

2026: Launch Year

• Q1: Voluntary participation begins (10 states)
• Q2: First IRP calculations published
• Q3: Vendor operations commence
• Q4: Initial evaluation report

2027-2029: Expansion Period

• Gradual geographic expansion
• Drug coverage increases
• Payment blend shifts toward IRP
• Continuous refinement based on data

2030-2031: Full Implementation

• National scope achieved
• Comprehensive drug coverage
• Full IRP integration
• Evaluation for permanent adoption

Expected Outcomes

Financial Impact

• Medicare Savings: $15-25 billion over 5 years
• Beneficiary Savings: Average 40% reduction in cost-sharing
• Provider Revenue: Stable through new payment structure

Access and Quality

• Maintained or improved drug access
• Reduced financial toxicity for beneficiaries
• Appropriate utilization patterns
• Enhanced care coordination

Market Effects

• Gradual price convergence with international markets
• Increased biosimilar adoption
• Sustained but targeted innovation
• Improved price transparency

Risk Mitigation Strategies

Manufacturer Responses

• Phased implementation reduces shock
• Innovation incentives preserved
• Small manufacturer protections
• International coordination efforts

Provider Concerns

• Adequate transition period
• Financial guarantees and support
• Reduced administrative burden
• Quality-based incentives

Beneficiary Protection

• Robust exceptions process
• No disruption to current therapies
• Enhanced patient support services
• Clear appeals procedures

Conclusion

The Medicare Part B Global Price Alignment Model represents a balanced approach to drug pricing reform that learns from international experience while respecting the unique aspects of the U.S. healthcare system. By gradually aligning prices with international benchmarks while protecting access and innovation, this model can achieve sustainable cost reductions without compromising quality of care.

The phased implementation allows for continuous learning and adjustment, while the vendor model option introduces competition and efficiency into the distribution system. Most importantly, the model prioritizes beneficiary access and affordability while creating a more rational payment system for providers.

Success will require careful implementation, robust stakeholder engagement, and flexibility to adapt based on real-world experience. With proper execution, this model can serve as a blueprint for broader drug pricing reform across the healthcare system.